ORPOF Message Board Post 10030184 | OSE Immunotherapeutics...
home / stock / orpof / orpof message board
Dyami
(investorshub)
Posted on: May/26/2021 08:40:58
Source: investorshub
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=164030494
https://www.globenewswire.com/news-release/2021/05/26/2236023/0/en/OSE-Immunothe
News, Short Squeeze, Breakout and More Instantly...
OSE Immunotherapeutics SA Company Name:
ORPOF Stock Symbol:
Market:
-
OSE Immunotherapeutics’ Global License to Develop a Novel Monoclonal Antibody for the Treatment of Chronic Inflammation Becomes Effective NANTES, France, April 16, 2024 – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), a clinical-stage immunotherapy company, to...
-
OSE Immunotherapeutics Announces Peer-Reviewed Publication on Novel Myeloid Immune Checkpoint CLEC-1 in Journal of Immunology Nantes, France – April 2, 2024 – 7:30 am CET – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) to...
-
Financial highlights €18.7 million available cash as of December 31 st , 2023, not including the upcoming $48 million payment as part of the recent collaboration and license partnership (February 2024) with AbbVie 1 , nor the €5.8 million of R&D Tax credit, p...